NeoGenomics (NEO) – Press Releases
-
NeoGenomics Announces Senior Leadership Promotions
-
NeoGenomics to Report First Quarter 2024 Financial Results on April 30, 2024
-
NeoGenomics Showcases Commitment to Transforming Cancer Patient Care at AACR 2024 Annual Meeting
-
NeoGenomics Releases Inaugural Environmental, Social, and Governance (ESG) Report
-
NeoGenomics to Participate in the TD Cowen 44th Annual Health Care Conference
-
NeoGenomics Reports Fourth Quarter and Full Year 2023 Results
-
NeoGenomics Signs Working with Cancer Pledge in Support of Employees
-
Multiple Myeloma Therapeutics Market Expected to Reach $4.26 Billion in 2030
-
NeoGenomics to Report Fourth Quarter and Full Year 2023 Financial Results on February 20, 2024
-
NeoGenomics to Participate in the 42nd Annual J.P. Morgan Healthcare Conference
-
NeoGenomics to Appeal Ruling
-
NeoGenomics to Present New Data at San Antonio Breast Cancer Symposium Highlighting Utility of RaDaR for Therapy Response
-
NeoGenomics to Participate at the Piper Sandler 35th Annual Healthcare Conference
-
NeoGenomics Reports Third Quarter 2023 Results
-
NeoGenomics Announces the Commercial Availability of Two New Tests, Expanding Its Next-Generation Sequencing and Lung Cancer Portfolios
-
NeoGenomics to Report Third Quarter 2023 Financial Results on November 6, 2023
-
NeoGenomics Reports Second Quarter 2023 Results
-
NeoGenomics Announces Medicare Coverage for RaDaR Assay for Minimal Residual Disease and Recurrence in Breast Cancer
-
NeoGenomics to Report Second Quarter 2023 Financial Results on August 8, 2023
-
Press release Biocartis Group NV: Biocartis appoints George Cardoza as new CFO and Head of Service Delivery
-
NeoGenomics Expands Board of Directors with Appointments of Three Independent Directors
-
NeoGenomics' RaDaR Assay for Minimal Residual Disease Receives First Commercial Coverage
-
NeoGenomics and German Breast Group Announce New Data Demonstrating Clinical Potential of the RaDaR MRD Assay in HR+/HER2- Breast Cancer
-
NeoGenomics to Participate at the Goldman Sachs 44th Annual Global Healthcare Conference
-
NeoGenomics to Showcase the Transformational Impact of RaDaR(R) Assay for Molecular Residual Disease and Recurrence Monitoring at ASCO
-
NeoGenomics Reports First Quarter 2023 Results
-
NeoGenomics to Participate at the BofA Securities 2023 Healthcare Conference
-
Neo Performance Materials and Hudson Resources Advance the Greenland Sarfartoq Rare Earth Project After Receiving Government Approval for License Transfer
-
NeoGenomics to Announce First Quarter 2023 Financial Results
-
NeoGenomics to Participate at the 22nd Annual Needham Virtual Healthcare Conference
-
NeoGenomics to Share Nine Abstracts at the American Association of Cancer Research (AACR) Annual Meeting 2023
-
NeoGenomics to Host Investor Day on April 4, 2023
-
Massive Bio and NeoGenomics Announce Collaboration to Accelerate Oncology Drug Discovery and Improve Patient Care
-
NeoGenomics Announces Commercial Availability of the RaDaR(R) Molecular Residual Disease Test
-
NeoGenomics Expands NGS Portfolio with Launch of Neo Comprehensive(TM) - Solid Tumor CGP and Neo Comprehensive(TM) - Myeloid Disorders CGP
-
NeoGenomics to Present at the 44th Annual Raymond James Institutional Investors Conference
-
NeoGenomics Reports Fourth Quarter and Full Year 2022 Results
-
RaDaR(R) Assay Demonstrates Clinical Potential for Helping Oncologists Determine Whether or Not Muscle-Invasive Bladder Cancer Patients Undergo Radical Surgery
-
NeoGenomics Schedules its Fourth Quarter and Full Year 2022 Earnings Release for February 23, 2023
-
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against F45 Training, Silvergate, NeoGenomics, and Iris and Encourages Investors to Contact the Firm
-
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against F45 Training, Silvergate, NeoGenomics, and Iris and Encourages Investors to Contact the Firm
-
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against F45 Training, Silvergate, NeoGenomics, and Iris and Encourages Investors to Contact the Firm
-
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against F45 Training, Silvergate, NeoGenomics, and Iris and Encourages Investors to Contact the Firm
-
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Silvergate, NeoGenomics, Iris, and NewAge and Encourages Investors to Contact the Firm
-
ROSEN, A LONGSTANDING LAW FIRM, Encourages NeoGenomics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – NEO
-
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against F45 Training, Silvergate, NeoGenomics, and Iris and Encourages Investors to Contact the Firm
-
NeoGenomics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
NeoGenomics Announces Chief Financial Officer Transition
-
RaDaR(R) Assay Demonstrates Clinical Potential for Detecting Disease Recurrence Across All Types of Early Breast Cancer, Including Triple Negative Disease
-
NeoGenomics and ImmunoGen Launch New Program Giving Ovarian Cancer Patients Access to Novel FR Biomarker Testing to Support the Launch of ELAHERE(TM)
Back to NEO Stock Lookup
